@susangkomen.bsky.social
Breast cancer research Breast cancer care & financial support Breast health advocacy & public policy
For someone with breast cancer, genomic testing can be a personalized guide that helps themchoose a treatment path with the greatest benefit while possibly avoiding unnecessary detours.
Read more in the latest Know More blog: https://www.komen.org/blog/know-more-genomic-testing/
4 years ago, we released a first-of-its-kind report highlighting the breast cancer disparities bet. Black & white women. Today, we’re sharing an update: in 9 major U.S. metro areas where outcomes were the worst, more Black lives are being saved from breast cancer.
Read more: https://bit.ly/4ojeKsz
October is National Breast Cancer Awareness Month and it's time to take action. From advocating for cancer research funding to supporting equitable care for all, your voice matters!
Visit komen.org to join the fight. Because ending breast cancer needs all of us.
In case you missed it, check out the latest Breast Cancer Breakthroughs focused on how ctDNA is poised to revolutionize breast cancer care and read our blog to learn what it means for patients.
Watch the event & read the blog here: https://bit.ly/48C56MO
Imlunestrant was just approved by the FDA to treat ER-positive, HER2-negative ESR1-mutated metastatic breast cancer. The approval was based on results from the phase 3 EMBER-3 clinical trial.
Read more on our What's New Page: https://bit.ly/3IW3ToM
Breast cancer is rising in women under 50, but thanks to lifesaving clinical trials, there’s hope on the horizon.
In our next Spotlight on Clinical Trials, we explore four current clinical trials that focus specifically on the needs of young women. https://bit.ly/42LaOrS
NEW Breast Cancer Breakthroughs Sept. 25! Learn about how simple blood tests are being used to improve breast cancer care.
Info here: https://bit.ly/3X1yPW0
Discover how complementary therapies can support and empower breast cancer patients through treatment and recovery in our next Spotlight on Clinical Trials blog, where we explore three clinical trials testing their safety and effectiveness.
Learn more: https://bit.ly/3KacV26
Komen is joining #RallyMedRes to call on Congress to protect lifesaving research! Research funded by the NIH is at the cornerstone of new advances for #breastcancer care.
Take action and tell Congress to protect lifesaving research! #FundNIH #KomenAdvocacy
Nueva Vida is 1 of the 8 orgs in the ShareForCures alliance, and they are dedicated to supporting Latinos whose lives have been affected by cancer. Breast cancer affects people from all backgrounds, yet not every community is appropriately represented in research.
Learn more: https://bit.ly/3K8umQA
Breast cancer is the leading cause of cancer death among Hispanic women in the U.S. We want to change that.
This Hispanic Heritage Month, we encourage the Hispanic & Latino communities to take charge of their breast health, get screened & learn their family health histories. https://bit.ly/44Oxsy1
The stage of breast cancer when it is diagnosed is an important factor when determining prognosis.
Learn about what each of these stages means: https://bit.ly/46iiNhb
We will never forget those we lost on Sept. 11, 2001.
11.09.2025 14:09 — 👍 1 🔁 0 💬 0 📌 0
Learn more about HER2+ MBC and the latest breakthroughs in research, clinical trials and treatment strategies at our upcoming MBC Impact Series.
🗓️ September 17th at 1pm CT / 2pm ET
Register today: https://bit.ly/4m6PzaX
Thank you to our partner AstraZeneca for supporting the MBC Impact Series.
Funding for #breastcancer early detection & research programs is moving forward in Congress. As Congress continues negotiations for the federal budget, we urge lawmakers to protect & invest in these lifelines. Read our statement: https://bit.ly/4m67Bdz
10.09.2025 15:03 — 👍 0 🔁 0 💬 0 📌 0
Susan G. Komen applauds today’s #SCOTUS decision to safeguard no-cost preventive care for more than 150 million Americans including #breastcancer patients, #survivors and those who are looking after their #breasthealth. Read more here: www.komen.org/news/susan-g...
27.06.2025 14:59 — 👍 2 🔁 1 💬 2 📌 0
Breast surgery is often a part of breast cancer treatment, but recovery can bring unexpected challenges. Get answers and tips in our Know More blog covering 4 surprising challenges and how to manage them.
Read more: bit.ly/46eyc3y
A Komen-supported study from UPMC shows how the “Hope for OTHERS” rapid autopsy program is reshaping metastatic breast cancer research through post-mortem tissue donation unlocking new treatment insights. bit.ly/44iUcb0
25.06.2025 19:02 — 👍 0 🔁 0 💬 0 📌 0
In addition to this research investment, we also fund direct patient support through our Patient Care Center as well as breast cancer education, patient navigation, and public policy advocacy.
Learn more about the grants and their recipients: www.komen.org/blog/komen-b... (3/3)
“Research saves lives, and now more than ever, we must invest in science that brings hope to patients — especially those facing the most aggressive forms of breast cancer,"" said Paula Schneider, President and CEO of Komen. (2/3)
23.06.2025 14:32 — 👍 0 🔁 0 💬 1 📌 0
We are proud to announce our 2025 breast cancer research grants supporting cutting-edge projects that prioritize the most pressing challenges facing patients, including metastatic breast cancer, health inequities and the need for more precise, personalized treatment strategies. 🧵(1/3)
23.06.2025 14:32 — 👍 0 🔁 0 💬 1 📌 0
@fatimacardoso.bsky.social shared results from the phase 3 OASIS-4 trial: Elinzanetant significantly reduced hot flash frequency and severity in women on hormone therapy for HR+ breast cancer. Results seen as early as week 1 and sustained through 52 weeks. #ASCO25
03.06.2025 02:11 — 👍 1 🔁 0 💬 0 📌 0
Paola Zagami presented data supporting that in young women with HR+ breast cancer and BRCA mutations, adding ovarian suppression (OFS) to endocrine therapy improved disease-free and overall survival compared to tamoxifen alone. Supports OFS as key in adjuvant care for this group #ASCO25
03.06.2025 02:10 — 👍 0 🔁 0 💬 0 📌 0
Jai Min Ryu shared 10-year ASTRRA trial results at #ASCO25: Adding 2 years of ovarian suppression to tamoxifen improved 10-year disease-free survival in premenopausal HR+ breast cancer. Greatest benefits observed in women 40–45 with high-risk tumors.
03.06.2025 02:06 — 👍 1 🔁 0 💬 0 📌 0
Today, Prudence Francis shared 15-year results from SOFT & TEXT trials: For premenopausal women with HR+ early breast cancer- combining ovarian suppression with exemestane lowered recurrence risk more than tamoxifen alone. Greatest benefits seen in younger women & high-grade tumors #ASCO25
03.06.2025 02:06 — 👍 0 🔁 0 💬 0 📌 0
Dr. Rita Mukhtar showed that ctDNA testing after chemo could help predict if breast cancer patients have high or low nodal burden. This info could help some patients safely skip full axillary lymph node dissection, avoiding side effects like lymphedema #ASCO25
02.06.2025 23:37 — 👍 0 🔁 0 💬 0 📌 0
Dr. Monika Graeser shared results from 3 trials in HER2+ early breast cancer: A 12-week paclitaxel + HER2 therapy led to 5-year survival over 95%. Some patients skipped chemo entirely and still had similar survival if no cancer was found after treatment #ASCO25
02.06.2025 23:36 — 👍 0 🔁 0 💬 0 📌 0
Komen grantee @ntungmd shared at #ASCO25: THP chemo led to complete response in 64% of HER2+/ER- and 32% of HER2+/ER+ breast cancer cases. The HER2DX test helps predict who is most likely to benefit- guiding more personalized care.
02.06.2025 23:35 — 👍 0 🔁 0 💬 0 📌 0
Today at #ASCO25, Dr. Kun Wang shared results from the neoCARHP trial: In HER2+ early breast cancer, skipping carboplatin (THP) was just as effective as the full combo (TCbHP)—with fewer side effects. THP could offer a gentler, safer path for many patients
02.06.2025 23:34 — 👍 0 🔁 0 💬 0 📌 0
Congrats to former Komen Scholar Susan Domchek on her #ASCO25 ACS Award! Her work tackles challenges in genetic cancer prevention by balancing risk assessment (like polygenic scores) with better non-surgical options (vaccines, PARP inhibitors). @pennmedicine.bsky.social
02.06.2025 17:00 — 👍 1 🔁 0 💬 0 📌 0
